Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.
about
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanesWhy cancer and inflammation?Wound repair: role of immune-epithelial interactionsE-type prostanoid receptor 4 (EP4) in disease and therapyPotential role of aspirin in the prevention of aneurysmal subarachnoid hemorrhage.Increased sensitivity to dextran sodium sulfate colitis in IRE1beta-deficient miceThe flavonoid luteolin worsens chemical-induced colitis in NF-kappaB(EGFP) transgenic mice through blockade of NF-kappaB-dependent protective moleculesIntestinal epithelial-derived TAK1 signaling is essential for cytoprotection against chemical-induced colitisInflammatory bowel diseaseToll-like receptor-4 promotes the development of colitis-associated colorectal tumors.Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruitKeratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats.Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation.Peroxisome proliferator-activated receptor δ promotes colonic inflammation and tumor growthCux1 transcription factor is induced in inflammatory bowel disease and protects against experimental colitis.Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells.Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression.Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer.NOD-like receptors in intestinal homeostasis and epithelial tissue repair.Prostaglandins and inflammation.Crucial role of macrophage selenoproteins in experimental colitis.Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease.Transactivation of EGFR by LPS induces COX-2 expression in enterocytes.Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation.Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sitesCox-2 deletion in myeloid and endothelial cells, but not in epithelial cells, exacerbates murine colitis.The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut15-Deoxy-Δ12,14-prostaglandin J2 inhibits macrophage colonization by Salmonella enterica serovar Typhimurium.Current concepts in cyclooxygenase inhibition in breast cancer.Longitudinal study of circulating protein biomarkers in inflammatory bowel disease.Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells.Regulated spatial distribution of cyclooxygenases and lipoxygenases in Crohn's ulcer.Lactobacillus paracasei CBA L74 metabolic products and fermented milk for infant formula have anti-inflammatory activity on dendritic cells in vitro and protective effects against colitis and an enteric pathogen in vivoSeverity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signalingThe role of COX-2 in intestinal inflammation and colorectal cancerMyd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury.The role of PGE2 in intestinal inflammation and tumorigenesis.Cyclooxygenase-2 deficiency leads to intestinal barrier dysfunction and increased mortality during polymicrobial sepsis.
P2860
Q24671911-1733826E-0021-4B54-BF80-BE70D83D4620Q24680891-EA9CEC02-D132-4D49-83FF-C213B66CE335Q26801818-BFC356EF-30AF-411F-BE8E-AC6EB89A5855Q26851156-FD6BA481-F05B-4793-99E6-C82A807077EFQ26998381-0CFBD8EA-239C-4161-B707-70531C31FAEFQ28359871-3E02A269-D34B-4F87-8246-F65A15C6CF14Q28469238-778044E7-2DE3-4DD1-A773-051BC8095D42Q28474823-F16A9D48-8B64-415B-BDC7-B52F9DDEE627Q29615500-01FFA590-7B29-497A-9D49-7AD19AEE77A6Q30481023-D82EA8F5-8948-4D63-BB54-99DCF77F8AEAQ30573518-DD70C271-F355-4924-8961-8499784544C6Q31503184-DD1E90EB-E3FC-4FA2-8D10-6244CB19A57CQ33625837-5B097718-F2DB-421D-9F9C-020013E51EDEQ33627388-17FE4DF4-4F88-4389-9B38-53B81F34A6B1Q33694518-50E202EF-54CA-44E1-ACCC-210C732C01A1Q33717722-4AB7FB56-65FB-4C3E-889B-77AD5C4517CFQ33759698-3AC6CB0E-107B-4A56-AF09-16F2AF986FDAQ33798596-FFC72D3B-A628-42E7-A1D7-35FC1205E77CQ33907548-699C7306-6212-4BF9-B996-07831C55C0C9Q34179727-54CD9AB7-7ECD-40FF-AD5D-37492FD16C6BQ34218777-5065DFDC-5E01-40F4-9997-8B02ACE56927Q34233126-4CBFDDB1-A64E-4935-9D6B-668A7BFF5F35Q34295500-7480DE83-4145-4BBE-95E2-81976C2FB3C9Q34402440-6C0A75B0-476C-413C-9129-3F5BEE109FBEQ34441916-B8C9E049-70C5-4D11-BDE8-0B2D5C6D614FQ34541337-0AD965BA-BAEA-492F-B6AB-2E9885A2728DQ34617230-F219A45C-01C0-481A-ABC4-4A5D07983964Q34790350-ED91470C-981E-4072-9074-DD97E31017DCQ34903814-1DCFF69E-C796-4D90-85D9-E53B7E2E4ABEQ34969789-4D2C6E6F-0291-4222-B244-1504818A8AC3Q35032838-36FB01B9-3F6A-47FE-8692-21765FEF736CQ35047018-26602442-BE7C-46EE-B26E-C7DF9CBE01DDQ35070568-375C1F24-91E5-41D5-98CF-34D8D4DC06A8Q35092636-12DA5C22-58BB-42B3-8BBD-45A9B0FFCDAAQ35103340-025A433C-8C38-47A1-AFE2-C2C972C13B65Q35168195-A5D58FEE-F3E3-4014-8041-E6BD454C1FCDQ35234704-7EA47C47-0DF0-4EC9-A0A6-4388A1921B51Q35250974-4A171165-EE3A-4EDA-B379-3A72A44BEB35Q35269711-71BF0D1D-02CE-4952-AB84-E1509C40F803Q35523910-B64454EB-02DC-43D6-92E7-F17CEC5112D1
P2860
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@ast
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@en
type
label
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@ast
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@en
prefLabel
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@ast
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@en
P2093
P2860
P356
P1476
Impaired mucosal defense to ac ...... ygenase-1 or cyclooxygenase-2.
@en
P2093
L A Dieleman
R B Sartor
R Langenbach
S G Morham
P2860
P304
P356
10.1172/JCI6899
P407
P577
2000-02-01T00:00:00Z